Immunoabsorption Therapy for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Retrospective Study
Dongxue Wang
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYunjin Xiong
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorJing Liu
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYiduo Feng
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorChangqin Zhang
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYin Zhang
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorXia Ding
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorXiaoyuan Wu
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorAkehu Alemasi
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorQi Huang
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYu Wu
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorHuabing Wang
Center of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYong Gong
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorCorresponding Author
De-Cai Tian
Center of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Correspondence:
De-Cai Tian ([email protected])
Yilun Zhou ([email protected])
Search for more papers by this authorCorresponding Author
Yilun Zhou
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Correspondence:
De-Cai Tian ([email protected])
Yilun Zhou ([email protected])
Search for more papers by this authorDongxue Wang
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYunjin Xiong
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorJing Liu
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYiduo Feng
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorChangqin Zhang
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYin Zhang
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorXia Ding
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorXiaoyuan Wu
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorAkehu Alemasi
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorQi Huang
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYu Wu
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorHuabing Wang
Center of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYong Gong
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorCorresponding Author
De-Cai Tian
Center of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Correspondence:
De-Cai Tian ([email protected])
Yilun Zhou ([email protected])
Search for more papers by this authorCorresponding Author
Yilun Zhou
Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Correspondence:
De-Cai Tian ([email protected])
Yilun Zhou ([email protected])
Search for more papers by this authorABSTRACT
Introduction
The elimination of myelin oligodendrocyte glycoprotein (MOG) antibodies using immunoadsorption (IA) is a therapeutic approach, but has not yet been specifically evaluated in MOG antibody-associated disease (MOGAD). This study aimed to provide evidence on the efficacy and safety of IA therapy for MOGAD.
Methods
This retrospective study included patients diagnosed with MOGAD, who were treated with IA. Clinical data of the patients were collected. The extended disability score scale (EDSS) before and after IA therapy was used to evaluate neurological status.
Results
Six patients aged 14–53 years were enrolled in this study. Each patient received 3–7 sessions of IA therapy. Half of the patients showed significant clinical improvement after IA, with EDSS scores decreasing by more than 1.0, whereas the other patients were unresponsive to IA. Partial remission of visual acuity was obtained in three of the four patients with visual impairment. Repeated detection of MOG antibodies in one case showed that the titer declined from 1:100 to 1:32 after five sessions of IA. Only one episode of mild hypotension was observed in 29 IA sessions.
Conclusion
IA therapy may be a potential treatment option for patients with MOGAD.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
Anonymized data will be shared by the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| tap70063-sup-0001-Supinfo.docWord document, 49.3 KB |
Data S1. Supporting Information. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1A. Al-Ani, J. J. Chen, and F. Costello, “Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Current Understanding and Challenges,” Journal of Neurology 270, no. 8 (2023): 4132–4150.
- 2R. Marignier, Y. Hacohen, A. Cobo-Calvo, et al., “Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease,” Lancet Neurology 20, no. 9 (2021): 762–772.
- 3A. Cobo-Calvo, A. Ruiz, E. Maillart, et al., “Clinical Spectrum and Prognostic Value of CNS MOG Autoimmunity in Adults: The MOGADOR Study,” Neurology 90, no. 21 (2018): e1858–e1869.
- 4A. S. López-Chiriboga, M. Majed, J. Fryer, et al., “Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders,” JAMA Neurology 75, no. 11 (2018): 1355–1363.
- 5O. Corbali and T. Chitnis, “Pathophysiology of Myelin Oligodendrocyte Glycoprotein Antibody Disease,” Frontiers in Neurology 14 (2023): 1137998.
- 6E. Longbrake, “Myelin Oligodendrocyte Glycoprotein-Associated Disorders,” Continuum (Minneap Minn) 28 (2022): 1171–1193.
- 7S. Jarius, K. Ruprecht, I. Kleiter, et al., “MOG-IgG in NMO and Related Disorders: A Multicenter Study of 50 Patients. Part 1: Frequency, Syndrome Specificity, Influence of Disease Activity, Long-Term Course, Association With AQP4-IgG, and Origin,” Journal of Neuroinflammation 13, no. 1 (2016): 279.
- 8S. Jarius, K. Ruprecht, I. Kleiter, et al., “MOG-IgG in NMO and Related Disorders: A Multicenter Study of 50 Patients. Part 2: Epidemiology, Clinical Presentation, Radiological and Laboratory Features, Treatment Responses, and Long-Term Outcome,” Journal of Neuroinflammation 13, no. 1 (2016): 280.
- 9A. Cobo-Calvo, A. Ruiz, F. Rollot, et al., “Clinical Features and Risk of Relapse in Children and Adults With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease,” Annals of Neurology 89, no. 1 (2021): 30–41.
- 10Y. Hacohen, Y. Y. Wong, C. Lechner, et al., “Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease,” JAMA Neurology 75, no. 4 (2018): 478–487.
- 11S. Ramanathan, S. Mohammad, E. Tantsis, et al., “Clinical Course, Therapeutic Responses and Outcomes in Relapsing MOG Antibody-Associated Demyelination,” Journal of Neurology, Neurosurgery, and Psychiatry 89, no. 2 (2018): 127–137.
- 12J. J. Chen, E. P. Flanagan, S. J. Pittock, et al., “Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks,” American Journal of Ophthalmology 252 (2023): 213–224.
- 13S. Oji and K. Nomura, “Immunoadsorption in Neurological Disorders,” Transfusion and Apheresis Science 56, no. 5 (2017): 671–676.
- 14C. Osman, R. Jennings, K. El-Ghariani, and A. Pinto, “Plasma Exchange in Neurological Disease,” Practical Neurology 20, no. 2 (2020): 92–99.
- 15L. Connelly-Smith, C. R. Alquist, N. A. Aqui, et al., “Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Ninth Special Issue,” Journal of Clinical Apheresis 38, no. 2 (2023): 77–278.
- 16J. Liu, R. Zhou, Y. Gong, et al., “A Prospective Study on Tryptophan Immunoadsorption in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorders,” Journal of Clinical Apheresis 37, no. 3 (2022): 237–244.
- 17B. P. Çinar and Y. G. Yorgun, “What we Learned From the History of Multiple Sclerosis Measurement: Expanded Disability Status Scale,” Nöro Psikiyatri Arşivi 55, no. Suppl 1 (2018): S69–S75.
- 18M. Reindl, K. Schanda, M. Woodhall, et al., “International Multicenter Examination of MOG Antibody Assays,” Neurol Neuroimmunol Neuroinflamm 7, no. 2 (2020): e674.
- 19L. Bollo, P. Iaffaldano, M. Ruggieri, et al., “Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method,” Frontiers in Neurology 12 (2021): 633115.
- 20P. J. Waters, L. Komorowski, M. Woodhall, et al., “A Multicenter Comparison of MOG-IgG Cell-Based Assays,” Neurology 92, no. 11 (2019): e1250–e1255.
- 21F. Tea, J. A. Lopez, S. Ramanathan, et al., “Characterization of the Human Myelin Oligodendrocyte Glycoprotein Antibody Response in Demyelination,” Acta Neuropathologica Communications 7, no. 1 (2019): 145.
- 22S. Faissner, J. Nikolayczik, A. Chan, et al., “Plasmapheresis and Immunoadsorption in Patients With Steroid Refractory Multiple Sclerosis Relapses,” Journal of Neurology 263, no. 6 (2016): 1092–1098.
- 23F. Heigl, R. Hettich, R. Arendt, J. Durner, J. Koehler, and E. Mauch, “Immunoadsorption in Steroid-Refractory Multiple Sclerosis: Clinical Experience in 60 Patients,” Atherosclerosis Supplements 14, no. 1 (2013): 167–173.
- 24A. Bauer, D. Rudzki, K. Berek, et al., “Increased Peripheral Inflammatory Responses in Myelin Oligodendrocyte Glycoprotein Associated Disease and Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder,” Frontiers in Immunology 13 (2022): 1037812.
- 25M. Ringelstein, I. Ayzenberg, G. Lindenblatt, et al., “Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders,” Neurology Neuroimmunology & Neuroinflammation 9, no. 1 (2021): e1100.
- 26I. Kleiter, A. Gahlen, N. Borisow, et al., “Apheresis Therapies for NMOSD Attacks: A Retrospective Study of 207 Therapeutic Interventions,” Neurology Neuroimmunology & Neuroinflammation 5, no. 6 (2018): e504.
- 27S. Llufriu, J. Castillo, Y. Blanco, et al., “Plasma Exchange for Acute Attacks of CNS Demyelination: Predictors of Improvement at 6 Months,” Neurology 73, no. 12 (2009): 949–953.
- 28N. De Simone and R. Sarode, “Diagnosis and Management of Common Acquired Bleeding Disorders,” Seminars in Thrombosis and Hemostasis 39, no. 2 (2013): 172–181.
- 29A. Ohkubo, T. Okado, T. Sakurasawa, et al., “Removal Characteristics of Immunoadsorption With the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis,” Therapeutic Apheresis and Dialysis 23, no. 3 (2019): 271–278.
- 30J. Koessler, A. Kobsar, S. Kuhn, et al., “The Effect of Immunoadsorption With the Immusorba TR-350 Column on Coagulation Compared to Plasma Exchange,” Vox Sanguinis 108, no. 1 (2015): 46–51.
- 31A. Ohkubo, N. Kurashima, and T. Okado, “Immunoadsorption With a Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis,” Therapeutic Apheresis and Dialysis 22, no. 3 (2018): 301–302.
Online Version of Record before inclusion in an issue
